

1 **Effect of portable non-invasive ventilation on thoracoabdominal**
2 **volumes in recovery from intermittent exercise in patients with COPD**

3

4 **Chynkiamis N.¹, Lane ND.^{2,4}, Megaritis D.¹, Manifold J.¹, Loizou I.¹, Alexiou C.¹,**
5 **Riazati S.¹, LoMauro A.³, Bourke SC.^{2,4*}, Vogiatzis I.^{1,2*}**

6 ¹Department of Sport, Exercise and Rehabilitation, Northumbria University,
7 Newcastle Upon-Tyne.

8 ²Northumbria Healthcare NHS Foundation Trust, North Tyneside General Hospital,
9 Newcastle Upon-Tyne.

10 ³Dipartimento di Elettronica, Informazione e Bioingegneria, Politecnico di Milano,
11 Milano, Italy.

12 ⁴Translational and Clinical Research Institute, Newcastle University; United Kingdom.

13 * sharing senior authorship

14 **Running Head:** Effect of portable NIV during recovery from exercise in COPD

15 **Correspondence:** Dr. Nikolaos Chynkiamis (nikchy@thorax.org.gr) THORAX
16 Foundation, Research Centre of Intensive Care and Emergency Thoracic Medicine, 3,
17 Ploutarchou St., 2nd floor 106 75 Athens, Greece

18

19 **Abstract**

20 **Background:** We previously showed that use of portable non-invasive ventilation
21 (pNIV) during recovery periods within intermittent exercise improved breathlessness
22 and exercise tolerance in COPD patients compared to pursed-lip breathing (PLB).
23 However, in a minority of patients recovery from dynamic hyperinflation (DH) was
24 better with PLB, based on inspiratory capacity. We further explored this using
25 Optoelectronic Plethysmography to assess total and compartmental
26 thoracoabdominal volumes.

27 **Methods:** Fourteen COPD patients (mean±SD) (FEV₁: 55±22% predicted) underwent,
28 in a balanced order sequence, two intermittent exercise protocols on the cycle
29 ergometer consisting of five repeated 2-min exercise bouts at 80% peak capacity,
30 separated by 2-min recovery periods, with application of pNIV or PLB in the first
31 minute of recovery.

32 **Results:** Our findings identified 7 patients showing recovery in DH with pNIV (DH
33 responders) while 7 showed similar or better recovery in DH with PLB. When pNIV
34 was applied, DH responders compared to DH non-responders exhibited greater tidal
35 volume (by 0.8±0.3 L, p=0.015), inspiratory flow rate (by 0.6±0.5 L/sec, p=0.049),
36 prolonged expiratory time (by 0.6±0.5 sec, p=0.006) and duty cycle (by 0.7±0.6 sec,
37 p=0.007). DH responders showed a reduction in end-expiratory thoracoabdominal
38 DH (by 265±633 ml) predominantly driven by reduction in the abdominal
39 compartment (by 210±494 ml); this effectively offset end-inspiratory rib-cage DH.
40 Compared to DH non-responders, DH responders had significantly greater BMI by
41 8.4±3.2 kg/m², p=0.022 and tended towards less severe resting hyperinflation by
42 0.3±0.3 L.

43 **Conclusion:** COPD patients who mitigate end-expiratory rib-cage DH by expiratory
44 abdominal muscle recruitment benefit from pNIV application.

45
46

47 **Keywords:** Exercise, NIV, COPD, Opto-Electronic Plethysmography, Dynamic
48 Hyperinflation

49

50
51
52
53
54
55
56
57
58
59

60 **New and Noteworthy**

61 Compared to the pursed-lip breathing technique, acute application of portable non-
62 invasive ventilation during recovery from intermittent exercise improved end-
63 expiratory thoracoabdominal dynamic hyperinflation (DH) in 50% of COPD patients
64 (DH responders). DH responders, compared to DH non-responders, exhibited a
65 reduction in end-expiratory thoracoabdominal DH predominantly driven by the
66 abdominal compartment that effectively offset end-expiratory rib cage DH. The
67 essential difference between DH responders and DH non-responders was, therefore,
68 in the behaviour of the abdomen.

69 **Introduction**

70 Expiratory flow limitation (EFL) is an important pathophysiological hallmark in
71 Chronic Obstructive Pulmonary Disease (COPD), limiting exercise tolerance
72 secondary to increased dynamic hyperinflation (DH) (13, 38). DH is manifested by
73 increased end-expiratory lung volume that reduces inspiratory reserve volume (IRV).
74 This forces COPD patients to breathe close to their total lung capacity (TLC),
75 increasing both work of breathing and breathlessness (38). Additionally, DH may
76 cause adverse central hemodynamic effects by reducing venous return, thus
77 impairing the normal increase in stroke volume and cardiac output during exercise
78 (1, 50). Non-invasive ventilation (NIV) is one of the ergogenic approaches that has
79 been implemented to reduce DH and breathlessness, thus improving exercise
80 tolerance in COPD (3).

81 A limited number of studies have assessed the effect of NIV on the magnitude of DH
82 during exercise by measuring inspiratory capacity (IC) (38) in patients with COPD
83 with conflicting evidence. Accordingly, application of NIV during exercise has shown
84 to either increase DH (43), or decrease DH (39), albeit the change in IC in the latter
85 study (39) still indicated significant DH above resting values (38). IC manoeuvres are,
86 however, effort dependent and therefore the estimate of DH may be inaccurate,
87 especially during intense exercise.

88 Application of a portable NIV (pNIV) device (VitaBreath, Philips Respironics
89 Morrisville, PA, USA) was recently shown to increase intermittent exercise tolerance
90 and improve breathlessness in comparison to the pursed lip breathing (PLB)
91 technique in 16/24 COPD patients when applied in the first minute of recovery
92 periods during successive bouts of intermittent exercise (10, 48). VitaBreath is a
93 portable, handheld, battery-powered, pNIV device that provides an expiratory
94 positive airway pressure (EPAP) of 8 cmH₂O and inspiratory positive airway pressure
95 (IPAP) of 18 cmH₂O (17). The VitaBreath device is no longer commercially available,
96 but similar devices may come to market. Nevertheless, the aforementioned studies
97 (10, 48) provided proof of concept on how NIV can be applied intermittently during
98 recovery from exercise in patients with COPD, and how to identify patients most
99 likely to respond to NIV. Furthermore, considering that use of pNIV in activities of
100 daily living improves anxiety around breathlessness, as well as perceived time of
101 recovery from it (48), ventilatory support during recovery from exercise is potentially
102 of value to the COPD patient.

103 We previously showed that whilst the majority of COPD patients experienced a
104 greater reduction in DH with pNIV compared to PLB (DH responders) based on
105 measurement of IC, in 8/24 of patients the improvement in DH was greater with PLB
106 than pNIV (DH non-responders); it may be that the fixed IPAP and EPAP were
107 suboptimal, at least for DH non-responders (10, 48). Interestingly, DH non-

108 responders tended to have greater resting airway obstruction and baseline lung
109 hyperinflation, whilst during exercise they exhibited greater restrictions to tidal
110 volume expansion compared to DH responders. Tidal volume expansion during
111 exercise depends on the degree of exercise-induced EFL (12, 18, 33) and the ability
112 to decrease end-expiratory thoracoabdominal volume by recruitment of expiratory
113 abdominal muscles (12, 27, 49). Accordingly, it was suggested that DH responders
114 would represent those patients exhibiting greater capacity to increase tidal volume
115 by recruiting expiratory abdominal muscles (11). However, in our earlier studies (10,
116 48) we did not assess the degree of expiratory abdominal muscle recruitment.
117 Furthermore, DH was assessed one minute following pNIV and PLB application by
118 performing inspiratory IC manoeuvres (36). Thus, the acute effect of pNIV
119 application on DH was not investigated.

120 Optoelectronic Plethysmography (OEP) allows breath-by-breath assessment of end-
121 inspiratory and end-expiratory total and compartmental (rib cage and abdominal)
122 thoracoabdominal volumes without the necessity to perform IC manoeuvres (2). The
123 purpose of the present study was to assess total and compartmental
124 thoracoabdominal volumes during acute application of pNIV during recovery from
125 exercise. We hoped to better understand why the rate of recovery from DH is slower
126 with pNIV compared to PLB in DH non-responders compared to DH responders (10,
127 48).

128 Earlier work has shown that application of continuous positive airway pressure
129 (CPAP: 7.5-10 cm H₂O) during exercise is associated with inflation of the rib cage
130 compartment with concomitant deflation of the abdominal compartment, secondary
131 to expiratory abdominal muscle recruitment, in the majority of COPD patients (43).
132 Accordingly, it was reasoned that during acute application of pNIV in recovery from
133 intermittent exercise, DH responders would exhibit greater recruitment of expiratory
134 abdominal muscles alongside greater expiratory flow rates when compared to DH
135 non-responders.

136

137 **Methods**

138 ***Study design***

139 This was a crossover study investigating the acute effect of pNIV compared to the
140 PLB technique on thoracoabdominal volumes in recovery from intermittent exercise.
141 Central hemodynamic responses, local respiratory muscle oxygen availability and
142 respiratory muscle electromyography activity were also assessed. Patients
143 underwent two sub-maximal intermittent exercise tests sustained at 80% of peak
144 work rate (WRpeak) on a cycle ergometer using both pNIV and the PLB technique
145 during recovery from exercise in a balanced order on the same day. The
146 investigations were carried out following the rules of the Declaration of Helsinki of
147 1975 (51), revised in 2013. NHS Research Ethics Committee approval (Ref:
148 19/NE/0091) and Clinical Trials registration (NCT03848819) were obtained. All
149 participants provided written informed consent.

150 ***Participants***

151 Inclusion criteria were stable COPD, aged 40 years or older with a smoking history of
152 at least 10 pack years, and who exhibited substantial exercise-induced DH at the
153 limit of incremental cycle exercise tolerance (i.e.: change in inspiratory capacity from
154 baseline >0.15 L or >4.5% of predicted resting IC) (38). Exclusion criteria included
155 COPD exacerbation within 6 weeks prior to exercise testing, unstable comorbidities
156 and inability to exercise.

157 ***Baseline Assessment – Visit 1***

158 Prior to exercise testing, participants attended North Tyneside General Hospital for
159 baseline assessment. This included spirometry, body plethysmography lung volume
160 measurements, diffusion capacity, resting electrocardiography (ECG) evaluation,
161 medical history and examination. Following medical assessment, patients performed
162 a ramp incremental exercise test with increments of 5-10 watts every minute to the
163 limit of tolerance on a cycle ergometer (Ergoselect 200, Ergoline GmbH, Bitz,
164 Germany) (48) to establish presence of DH (38, 48) and WRpeak.

165 ***Intermittent Exercise Protocol – Visit 2***

166 Patients underwent two intermittent exercise protocols on the cycle ergometer
167 (Ergoselect 200, Ergoline GmbH, Bitz, Germany). The exercise protocol consisted of
168 five repeated 2-min exercise bouts at 80% of predefined WRpeak, separated by 2-
169 min recovery periods, to allow application of pNIV or the PLB technique. During the
170 first minute of each recovery period, patients breathed through the pNIV device or
171 adopted the PLB technique. During the second minute of each recovery period
172 patients breathed normally. Before each exercise test patients underwent three-

173 minutes of baseline measurements (quiet breathing-QB) followed by a three-minute
174 warm-up period with no cycling load.

175 After the termination of the 5th exercise bout patients underwent 5 minutes of
176 measurements during recovery. Patients performed IC manoeuvres to allow
177 calculation of thoracoabdominal volumes at total lung capacity (TLC) during QB, the
178 second minute of each exercise bout and each recovery period as previously
179 described (40). Total and compartmental thoracoabdominal volumes were recorded
180 by OEP during QB, exercise and recovery periods. Circulatory responses and local
181 respiratory muscle oxygenation were measured non-invasively using impedance
182 cardiography technology and near-infrared spectroscopy, respectively throughout
183 QB, exercise and recovery periods. Electromyography (EMG) activity of respiratory
184 muscles (intercostal, scalene and rectus abdominis) was recorded during the first
185 minute of each recovery period using surface electromyography electrodes.
186 Peripheral oxygen saturation (SpO₂%) was continuously monitored by a pulse
187 oximeter (Onyx Vantage 9590, Nonin Medical Inc, USA). Finally, following each
188 exercise bout dyspnoea and leg discomfort were recorded on the modified 1-10 Borg
189 scale (6).

190 *pNIV and pursed lip breathing*

191 During the first minute of each recovery period in one of the exercise tests, pNIV was
192 applied via the VitaBreath device. The VitaBreath is a portable, handheld, battery-
193 powered, non-invasive ventilation device (pNIV) intended to reduce activity-related
194 shortness of breath (17). It delivers fixed high inspiratory (18 cm H₂O) and expiratory
195 (8 cm H₂O) pressures, but it can only be used during recovery periods interspersing
196 bouts of physical activity.

197 Patients practiced using the VitaBreath device and the correct adoption of the PLB
198 technique with guidance from a respiratory nurse during the first visit. During the
199 second visit a respiratory physician was present to ensure that patients were able to
200 follow the instructions provided by the researchers and perform the pNIV and PLB
201 techniques correctly.

202 ***Thoracoabdominal volumes***

203 During both intermittent exercise tests, thoracoabdominal wall kinematics were
204 assessed by the OEP system (BTS, Milano, Italy) during QB, the second minute of
205 each exercise bout and throughout the recovery periods as follows: the movement
206 of 89 retro-reflective markers placed over the anterior, lateral and posterior chest
207 wall was recorded. Each marker was tracked by eight video cameras (Smart System
208 BTS, Milan, Italy), four in front of the subject and four behind. Subjects used grasp
209 handles positioned at the mid sternum level to lift their arms away from the rib cage

210 so that lateral markers could be visualised. Dedicated software reconstructed the
211 three-dimensional coordinates of the markers in real time by stereophotogrammetry
212 and calculated total and compartmental thoracoabdominal volume and volume
213 variations using Gauss's theorem. The chest wall was modelled as being composed
214 of two compartments—the rib cage and the abdominal compartments. Total
215 thoracoabdominal volume is the sum of these two compartmental volumes (49).

216 ***Circulatory responses***

217 During both intermittent exercise tests, participants were connected to a portable
218 device using impedance cardiography technology (Physio Flow, Enduro, PF-07,
219 Manatec Biomedical, Folschviller, France). The validity of cardiac output recordings
220 using Physio Flow, in comparison to the dye dilution method and the direct Fick
221 method, has been confirmed in both healthy subjects and those with
222 cardiorespiratory disease (9, 26, 46). Cardiac output (CO), heart rate and stroke
223 volume were recorded continuously as previously detailed (34). Six electrodes were
224 placed on patients, two on the left carotid artery (Z1 and Z2), two in the breast area
225 (EKG1 and EKG2) and two in the chest area [Z3 and Z4-EKG3 (neutral)] (34).

226 ***Local respiratory muscle oxygen availability***

227 Local respiratory muscle oxygen availability of the intercostal muscles (7th intercostal
228 space) and rectus abdominis was assessed throughout QB, exercise and recovery
229 periods by a NIRO 200 spectro-photometer (Hamamatsu Photonics KK, Hamamatsu,
230 Japan). The NIRO 200 uses Spatially Resolved Spectroscopy method to detect
231 changes in Tissue Oxygenation Index (TOI), Oxygenated haemoglobin (HbO₂), and
232 Deoxygenated haemoglobin (HHb) and its validity has been previously established
233 (29). Two sets of NIRS optodes were placed, one on the skin over the 7th left
234 intercostal space at the midaxillary line and the other over the left rectus abdominis.
235 The optode separation distance was 4 cm, corresponding to a penetration depth of
236 approximately 2 cm. The left intercostal and rectus abdominis were used in order to
237 avoid potential blood flow contributions from the liver (25). NIRS values were zeroed
238 at the start point of each exercise protocol. NIRS data were sampled at 6 Hz and
239 exported in document file format and averaged for offline analysis at 60 s intervals.

240

241 ***Respiratory muscle electromyography***

242 EMG was used to assess respiratory muscle activation during application of pNIV or
243 PLB. Prior to placement of electrodes, the skin was cleaned. Surface electrodes
244 (Delsys Trigno, Delsys, Boston, MA, USA) were placed as previously been described
245 (8) on the surface over the right seventh intercostal space, 2 cm lateral to the
246 umbilicus, over the muscle mass of rectus abdominis and over the scalene muscle.

247 EMG data were recorded during quiet breathing and at the first minute of each
248 recovery period when pNIV or PLB were applied for 30 seconds. Finally, EMG data
249 were recorded at 2000Hz and were filtered at 25–500 Hz during each trial (Spike 2,
250 Cambridge Electronic Design, Cambridge, UK) (8). All EMG was processed using
251 custom written scripts in Matlab (The Mathworks, Inc. Natick, MA, USA). Data are
252 presented as fractional change in electromyographic activity from baseline values.

253 ***Statistical analysis***

254 Estimation of sample size within each breathing modality (i.e. pNIV and PLB) was
255 based on the results of our previous study (48). Using the minimum clinically
256 important difference in DH assessed by inspiratory capacity manoeuvres defined as
257 4.5% of predicted resting IC (mean: 120 ml within our previous cohort) and observed
258 SD: 110 ml (48), an alpha significance level of 0.05 (2-sided) and 80% power, a
259 minimum total sample size of 13 patients was required. Fourteen patients were
260 recruited in order to achieve balance in the order that the pNIV and PLB trials were
261 performed. Seven patients had previously participated in a study undertaken by our
262 group (48). Data are presented as mean \pm standard deviation (SD) unless otherwise
263 stated. DH responders were identified as patients showing a reduction in end-
264 expiratory thoracoabdominal volume with pNIV at least 120 ml greater than that
265 seen with PLB at the first minute of recovery, whereas DH non-responders were
266 those failing to show this degree of response with pNIV compared to PLB (10). The
267 120 ml dichotomous value was based on our earlier study (10) indicating that
268 patients showing an reduction in DH \geq 120 ml (40) when using pNIV compared to the
269 PLB technique were identified as DH responders. Patients showing a decrease in DH
270 $<$ 120 ml, or an increase, in DH using pNIV compared to PLB were defined as DH non-
271 responders. Independent sample t-tests were employed to compare baseline
272 characteristics between DH responders and DH non-responders. Two-way repeated
273 measures ANOVA followed by least significant difference (LSD) post-hoc analysis was
274 employed to assess differences in total and compartmental thoracoabdominal
275 volumes, breathing pattern, circulatory responses and local respiratory muscle
276 oxygenation between both the pNIV device and PLB exercise tests, and between DH
277 responders and DH-non responders. Activation of respiratory muscle EMG activity is
278 presented as percentage of change from baseline (QB) and was analysed using
279 paired sample t-tests. Data present mean values for thoracoabdominal and
280 compartmental volumes, circulatory responses, local respiratory muscle oxygen
281 availability, and respiratory muscle EMG activity for: QB, the 5 exercise bouts, the 1st
282 and 2nd minutes of all 5 recovery periods as well as the 3rd, 4th and 5th minute of
283 recovery following the final exercise bout. The level of significance for all analyses
284 was set at $p < 0.05$.

285

286 **Results**

287 Overall, patients had moderately severe airway obstruction and significant lung
288 hyperinflation at rest (Table 1). Peak exercise capacity was severely impaired;
289 patients exhibited exercise-induced DH and low peak oxygen consumption at the
290 limit of tolerance (Table 1). DH responders had significantly greater BMI and
291 inspiratory flow rate at rest (Table 1).

292 ***Thoracoabdominal volumes for all patients***

293 Across all 14 patients, total end-expiratory and end-inspiratory thoracoabdominal
294 and compartmental volumes were not significantly different during exercise
295 between PLB and pNIV trials (Figure 1). Compared to QB, end-expiratory
296 thoracoabdominal volume increased by an average of 266 ± 152 ml during exercise
297 indicating presence of DH (38). Thoracoabdominal IRV at the end of exercise was on
298 average 645 ± 439 ml (Figure 1a). Compared to QB at the end of exercise we found an
299 average increase of 326 ± 291 ml ($p=0.001$) in thoracoabdominal volume at TLC
300 (Figure 1a).

301 With acute pNIV application in the first minute of recovery total end-inspiratory
302 thoracoabdominal volume was greater compared to PLB application (by: 230 ± 207
303 ml; $p=0.047$) (Figure 1a), secondary to greater end-inspiratory rib cage volume (by:
304 266 ± 196 ; $p=0.005$) (Figure 1b). Total end-expiratory thoracoabdominal volumes
305 were not different ($p=0.673$) between acute PLB and pNIV applications in the first
306 minute of recovery (Figure 1a). During pNIV application there was a greater increase
307 in end-expiratory rib cage volume (by 198 ± 185 ml $p=0.047$ value) (Figure 1b)
308 compared to PLB, which was partially compensated by the lower end-expiratory
309 abdominal volume (by 141 ± 124 ml $p=0.022$) (Figure 1c). IRV (relative to TLC at the
310 end of exercise) was on average 257 ± 227 ($p=0.038$) ml lower with acute pNIV
311 application compared to PLB, indicating ventilatory constraints (36). At the 5th
312 minute of recovery following the last exercise bout, neither end-inspiratory nor end-
313 expiratory total thoracoabdominal volumes returned to levels recorded during QB
314 (Figure 1a).

315 ***Thoracoabdominal volumes during exercise***

316 During exercise total end-expiratory thoracoabdominal volumes were not different
317 ($p>0.05$) between pNIV and PLB trials for DH responders and DH non-responders,
318 (Figure 2). DH responders and DH non-responders exhibited an increase in end-
319 expiratory thoracoabdominal volume (by: 281 ± 135 ml and by: 248 ± 161 ml,
320 respectively) compared to QB, indicating exercise-induced DH (38) (Figure 2a & 2d).
321 However, DH responders significantly decreased ($p<0.05$) end-expiratory abdominal
322 volume during exercise compared to QB in both trials (Figure 2c), whereas DH non-

323 responders maintained end-expiratory abdominal volume unchanged from QB in
324 both trials ($p>0.05$) (Figure 2f). Exercise IRV was not different ($p=0.391$) between DH
325 responders (644 ± 513 ml) and DH non-responders (528 ± 353 ml) (Figure 2a & 2d).
326 During exercise DH responders exhibited greater inspiratory and expiratory flow
327 rates compared to DH non-responders (Figure 3 a & 3b).

328 ***DH responders in recovery from exercise***

329 Our analysis identified 7 patients as DH responders and 7 patients as DH non-
330 responders (Table 1). In DH responders, during acute application of pNIV compared
331 to PLB, total end-expiratory thoracoabdominal volume was lower by 209 ± 422 ml (38)
332 (Figure 2a), secondary to significantly lower end-expiratory abdominal volume with
333 pNIV compared to PLB (by: 219 ± 197 ml; $p=0.026$) (Figure 2c), thereby indicating
334 greater expiratory abdominal muscle recruitment. In DH responders during acute
335 application of pNIV compared to PLB, numerical differences did not reach statistical
336 significance for total end-inspiratory thoracoabdominal volume (by 224 ± 465 ml;
337 $p=0.250$) (Figure 2a) consequently to differences in end-inspiratory rib cage volume
338 (by 186 ± 368 ml; $p=0.230$) (Figure 2b). IRV with pNIV tended to be lower ($p=0.078$)
339 compared to PLB (by 302 ± 421 ml) (Figure 2a and Table 2). At the 5th minute of
340 recovery following the last exercise bout, neither end-inspiratory nor end-expiratory
341 total thoracoabdominal volumes returned to levels recorded during QB (Figure 2a).

342 ***DH non-responders in recovery from exercise***

343 In DH non-responders, during acute application of pNIV compared to PLB, total end-
344 expiratory thoracoabdominal volume was greater ($p=0.001$) by 356 ± 153 ml (Figure
345 2d) secondary to greater end-expiratory rib cage volume with pNIV compared to PLB
346 (by: 416 ± 86 ; $p=0.001$) (Figure 2e) and unchanged end-expiratory abdominal volume
347 (Figure 2f). During acute application of pNIV total end-inspiratory thoracoabdominal
348 volume was greater compared to PLB (by: 238 ± 218 ml; $p=0.047$) (Figure 2d),
349 secondary to greater end-inspiratory rib cage volume (by: 346 ± 199 ml; $p=0.004$)
350 (Figure 2e). There was no significant difference in IRV between pNIV and PLB
351 application ($p=0.252$) (Figure 2d and Table 2). At the 5th minute of recovery following
352 the last exercise bout, neither end-inspiratory nor end-expiratory total
353 thoracoabdominal volumes returned to levels recorded during QB (Figure 2d).

354 ***Differences between DH responders and non-responders in recovery from exercise***

355 Considering pNIV application alone, DH responders compared to DH non-responders
356 exhibited a reduction in end-expiratory thoracoabdominal DH (by 265 ± 633 ml)
357 predominantly driven by reduction in the abdominal compartment (210 ± 494 ml),
358 thereby effectively offsetting end-inspiratory rib cage DH.

359

360 ***Breathing pattern in DH responders and DH non-responders***

361 *DH responders:* During acute pNIV application compared to PLB, DH responders had
362 greater minute ventilation (by: 6.5 ± 6.4 L/min; $p=0.009$), secondary to greater tidal
363 volume (by: 0.5 ± 0.4 L; $p=0.002$) without any differences in breathing frequency,
364 inspiratory and expiratory time, or duty cycle (Table 2). During acute pNIV
365 application compared to PLB, DH responders exhibited greater inspiratory flow rate
366 (by: 0.4 ± 0.3 L/sec; $p=0.001$) and greater expiratory flow rate (by: 0.2 ± 0.2 L/sec;
367 $p=0.048$) (Figures 3a & 3b, Table 2). There were no differences either in average
368 values for breathlessness ($p=0.745$) or in leg discomfort ($p=0.880$) between pNIV and
369 PLB application in DH responders (Table 2).

370 *DH non-responders:* Compared to PLB, with acute pNIV application DH non-
371 responders increased their minute ventilation (by: 5.7 ± 4.5 L/min; $p=0.018$) by
372 adopting a more tachypnoeic breathing pattern (compared to DH responders) as
373 breathing frequency was greater with pNIV compared to PLB (by: 7 ± 6 breaths/min;
374 $p=0.002$) (Table 2). The tachypnoeic breathing pattern resulted in lower inspiratory
375 time (by: 0.3 ± 0.2 sec; $p=0.019$), lower expiratory time (by: 0.8 ± 0.6 sec; $p=0.001$) and
376 lower total duty cycle (by: 1.1 ± 0.8 sec; $p=0.001$) with pNIV application compared to
377 PLB (Table 2). Moreover, with pNIV application compared to PLB there was a trend
378 for greater inspiratory flow rate (by 0.2 ± 0.2 L/sec $p=0.064$), whilst expiratory flow
379 rate was significantly greater (by: 0.2 ± 0.2 L/sec; $p=0.011$) (Figures 3a & 3b, Table 2).
380 Following acute application of pNIV compared to PLB breathlessness was lower in DH
381 non-responders (by: 1.1 ± 0.9 ; $p=0.001$), whilst leg discomfort was unaffected
382 ($p=0.203$) (Table 2).

383 ***Differences in breathing pattern between DH responders and DH non-responders***

384 When pNIV was applied, DH responders compared to DH non-responders exhibited
385 greater tidal volume (by 0.8 ± 0.5 L, $p=0.015$), inspiratory flow rate (by 0.6 ± 0.5 L/sec,
386 $p=0.049$), prolonged expiratory time (by 0.6 ± 0.5 sec, $p=0.006$) and duty cycle (by
387 0.7 ± 0.6 sec, $p=0.007$) whilst breathing frequency was lower ($p=0.019$) (Table 2).

388 With pNIV application numerical differences for expiratory flow rate in DH
389 responders compared to DH non-responders (by 0.2 ± 0.5 L/min) did not reach
390 statistical significance ($p=0.389$). IRV relative to end-exercise TLC during acute pNIV
391 application was not different between DH responders and DH non-responders
392 ($p=0.968$) (Figures 2a and 2d).

393 ***Central haemodynamic responses***

394 CO was unaffected by acute pNIV application compared to PLB in both DH
395 responders and DH non-responders (Figure 4c & 4f). However, in DH responders,
396 throughout recovery from exercise, pNIV application resulted in significantly greater

397 CO compared to PLB ($p=0.024$) (Figure 4c) and did not return towards baseline at the
398 5th minute of recovery. In DH non-responders there were no differences in the
399 pattern of response in any of the central haemodynamic variables between pNIV and
400 PLB application in recovery from exercise (Figure 4 d-f), whereas CO returned
401 towards baseline at the 5th minute of recovery.

402 ***EMG muscle activity***

403 Surface muscle EMG revealed two different patterns of respiratory muscle activation
404 during recovery from exercise. DH responders exhibited greater inspiratory and
405 expiratory EMG muscle activity (delta of percentages from baseline between
406 conditions) with pNIV application compared to PLB as this was reflected by the
407 greater activation of intercostal (by: $20\pm 16\%$; $p=0.043$), scalene (by: $50\pm 33\%$;
408 $p=0.013$) and rectus abdominis (by: $67\pm 57\%$; $p=0.014$) muscles (Table 3). In contrast,
409 DH non-responders using pNIV compared to PLB exhibited reduced inspiratory
410 (intercostal and scalene) EMG muscle activity, and increased expiratory (abdominal)
411 EMG muscle activity. This was reflected by lower EMG activity of intercostal (by:
412 $32\pm 22\%$; $p=0.009$) and scalene (by: $32\pm 30\%$; $p=0.047$) muscles and greater EMG
413 activity of rectus abdominis muscle (by: $33\pm 31\%$; $p=0.049$) (Table 3). Accordingly,
414 greater EMG activity of the inspiratory muscles during pNIV compared to PLB was
415 evident in DH responders compared to DH non-responders for intercostal ($p=0.004$)
416 and scalene ($p=0.007$) muscles. There was no difference in the pattern of rectus
417 abdominis EMG muscle activity between DH responders and DH non-responders
418 with pNIV compared to PLB applications ($p=0.538$); both DH responders and DH non-
419 responders increased EMG abdominal muscle activity with pNIV compared to PLB
420 (Table 3). However, DH responders exhibited a two fold greater increase in EMG
421 abdominal muscle activity with pNIV compared to PLB in comparison to DH non-
422 responders (Table 3).

423 ***Respiratory muscle oxygen availability***

424 In DH responders, when pNIV was applied compared to PLB, deoxygenated
425 haemoglobin was greater in intercostal muscles (by: 2.3 ± 2.1 $\mu\text{mol/L}$; $p=0.048$) and
426 rectus abdominis muscle (by: 1.8 ± 1.7 $\mu\text{mol/L}$; $p=0.047$). In DH non-responders, pNIV
427 application compared to PLB caused greater levels of deoxygenated haemoglobin in
428 intercostal (by: 2.1 ± 1.5 $\mu\text{mol/L}$; $p=0.040$) and rectus abdominis (by: 4.6 ± 4.0 $\mu\text{mol/L}$;
429 $p=0.045$) muscles. There were no differences in the pattern and magnitude of
430 response of deoxygenated haemoglobin of intercostal and abdominal muscles
431 between DH responders DH non-responders.

432 **Discussion**

433 ***Main findings***

434 In line with our earlier studies (10, 48) we have identified two different patterns of
435 DH response to acute application of pNIV compared to PLB in recovery from exercise
436 in COPD: DH responders showing a greater improvement in DH using pNIV compared
437 to PLB of at least 120 ml and DH non-responders failing to show this degree of
438 response with pNIV compared to PLB. When pNIV was applied in recovery from
439 exercise, DH responders compared to DH non-responders exhibited greater tidal
440 volume, inspiratory and expiratory flow rates, prolonged expiratory time and duty
441 cycle, and experienced lower end-expiratory DH secondary to greater expiratory
442 abdominal muscle recruitment. DH responders had significantly greater BMI and
443 resting inspiratory flow rate, and less severe resting hyperinflation compared to DH
444 non-responders.

445 ***Study novelties***

446 To the best of our knowledge this is the first study to assess total and
447 compartmental thoracoabdominal volumes acutely during application of a NIV
448 method in recovery from exercise in patients with COPD. Use of optoelectronic
449 plethysmography allowed patients to breathe normally and carry out ventilatory
450 measurements without the need of a valve and mouthpiece. In contrast to our
451 previous studies (10, 48), the present study used optoelectronic plethysmography to
452 assess the magnitude of dynamic hyperinflation in recovery from exercise when
453 using pNIV or PLB without requirement of inspiratory capacity manoeuvres that are
454 effort dependent (1, 2). Finally, use of optoelectronic plethysmography allowed us to
455 evaluate the breathing pattern throughout the application of pNIV and PLB including
456 breath-by-breath recordings of expiratory and inspiratory time and flow rates, total
457 duty cycle, tidal volume, breathing frequency, and minute ventilation.

458 ***Differences in baseline characteristics between DH responders and non-responders***

459 One significant difference between DH responders and DH non-responders was
460 elevated BMI presented in the group of DH responders. A recent study (10) argued
461 that a possible mechanism that allowed DH responders compared to DH non-
462 responders to benefit from pNIV was the increased BMI (10). It has previously been
463 reported that the respiratory muscles of COPD with high BMI might have a
464 mechanical advantage in comparison to patients with normal BMI (35). This has been
465 attributed to the increased inspiratory capacity (i.e. lower resting hyperinflation) in
466 patients with high BMI, which was evident in the DH responders in the present
467 study. Moreover, patients with high BMI might have an advantage when using pNIV,
468 which applies a high expiratory positive airway pressure (8 cmH₂O) in comparison to
469 other NIV devices (7, 19, 22, 44, 45, 47). It is known that intrinsic positive end-

470 expiratory pressure (PEEPi) needs to be closely matched with extrinsic positive end-
471 expiratory pressure (PEEPe) (31). If PEEPe is significantly lower than PEEPi there will
472 be no improvement in operational lung volumes (14, 32). In contrast, if PEEPe is
473 much greater than PEEPi, dynamic hyperinflation will worsen and result in adverse
474 central haemodynamic responses (16, 28). Patients with higher BMI exhibit greater
475 PEEPi (35), thus NIV devices with higher expiratory positive airway pressure (PEEPe),
476 such as the VitaBreath device in the present study (8 cm H₂O), might be better suited
477 to patients with high BMI (10). Future devices may be able to tailor the expiratory
478 pressure to overcome expiratory flow limitation in individual patients.

479 ***DH responders***

480 Application of pNIV compared to PLB was associated with increased end-inspiratory
481 rib cage and total thoracoabdominal volumes in DH responders. This finding is
482 explained by the high fixed IPAP (18 cmH₂O) provided by the VitaBreath device, but
483 is in line with other NIV methods showing an inflation of the rib cage compartment
484 with NIV application (43). However, application of pNIV compared to PLB lessened
485 end-expiratory abdominal and total thoracoabdominal volumes in DH responders.

486 It is well known that COPD patients develop varying degrees of expiratory flow
487 limitation. This leads to DH at different ventilatory levels during exercise, but which
488 greatly differ among patients with COPD (21, 49). Indeed, Vogiatzis and colleagues
489 identified two different DH patterns during exercise and in recovery from exercise,
490 namely early and late DH (49). COPD patients who developed late DH during exercise
491 were those who compensated end-expiratory rib cage DH by expiratory abdominal
492 muscle recruitment (49). When using pNIV, DH responders in the present study
493 exhibited a similar pattern to that previously described for late DH (49); they were
494 able to compensate end-expiratory rib cage DH by recruiting their expiratory
495 abdominal muscles. Furthermore, during exercise and during acute pNIV application,
496 DH responders exhibited greater expiratory flow rates compared to PLB thereby
497 indicating lower degrees of expiratory flow limitation. Presumably, when using pNIV
498 compared to PLB, expiratory abdominal muscle recruitment in conjunction with
499 greater expiratory flow rate and marginally prolonged expiratory time was effective
500 in reducing end-expiratory DH in recovery from exercise (27). Greater expiratory
501 abdominal muscle recruitment with pNIV compared to PLB was in turn corroborated
502 by greater rectus abdominis muscle EMG activity alongside increased rectus
503 abdominis deoxygenated haemoglobin; this suggests greater oxygen extraction due
504 to increased muscle activation.

505 DH responders were less flow limited during exercise and during acute pNIV
506 application compared to DH non-responders, inferred by the greater inspiratory and
507 expiratory flow rates (Figure 3), allowing them to increase tidal volume more than
508 DH non-responders. Thoracoabdominal tidal volume during acute application of

509 pNIV was nearly two-fold greater in DH responders than DH non-responders (Table
510 2). DH responders were able to expand their tidal volume firstly by increasing their
511 end-inspiratory thoracoabdominal volume, and secondly by decreasing their end-
512 expiratory thoracoabdominal volume during acute application of pNIV. This increase
513 in tidal volume was the result of greater thoracoabdominal volume at total lung
514 capacity, allowing a larger increase in end-inspiratory volume up to the point of
515 reaching critical mechanical constraints (Figure 2 a) (38). Greater end-inspiratory
516 thoracoabdominal volume was also associated with greater intercostal and scalene
517 EMG muscle activity and inspiratory flow rates. The increased tidal volume during
518 acute pNIV application was the result of increased abdominal muscle recruitment,
519 which was greater in DH responders compared to DH non-responders (Figure 2c &
520 2f). This finding is further supported by the EMG data on rectus abdominis showing a
521 two-fold increase in EMG activity with pNIV compared to PLB in DH responders
522 versus DH non-responders. Thus, greater expiratory abdominal power output (the
523 product of their velocity of shortening and the force they develop) in DH responders
524 was expressed more as expiratory flow and less as pressure secondary to lower
525 dynamic airway compression (27). This is most likely the reason why we did not find
526 impaired central hemodynamic responses with pNIV compared to PLB in DH
527 responders. However, greater EMG rectus abdominis muscle activity with pNIV
528 compared to PLB application may account for the lack of difference in dyspnoea
529 levels despite lower DH, given that increased expiratory muscle activity during
530 positive-pressure breathing has been postulated to increase breathlessness (42).
531 Moreover, in DH-responders there was no meaningful difference in dyspnoea
532 between pNIV and PLB. This might be attributed to IRV with pNIV been lower
533 compared to PLB as a result of significantly greater tidal volume expansion with pNIV
534 application (Table 2) (40). Furthermore inspiratory muscle (intercostal and scalene)
535 activity was significantly greater with pNIV compared to the PLB technique (Table 3).
536 Increased inspiratory muscle effort has been shown to be associated with a rise in
537 perceived inspiratory difficulty reflecting increased dissociation between the
538 increased central neural drive and the blunted mechanical response of the
539 respiratory system (23, 37).

540

541 ***DH non-responders***

542 Application of pNIV compared to PLB was associated with increased end-inspiratory
543 and end-expiratory rib cage volumes. However, the increase in end-expiratory rib
544 cage volume was not compensated by a reduction in end-expiratory abdominal
545 volume as reported above for DH responders. This led to an increase in total end-
546 expiratory thoracoabdominal volume and thus DH, which limited tidal volume
547 expansion. In line with our earlier studies (10, 48) tidal volume expansion was

548 restricted with pNIV compared to PLB application; patients adopted a more
549 tachypnoeic-breathing pattern that reduced inspiratory and expiratory time as well
550 as duty cycle. However, both inspiratory and expiratory flow rates were greater with
551 pNIV compared to PLB secondary to the high fixed airway pressures delivered pNIV.

552 During pNIV compared to PLB, DH non-responders exhibited greater rectus
553 abdominis EMG activity (and deoxygenated haemoglobin) which, despite the
554 increase in expiratory flow rate, was not successful in mitigating end-expiratory
555 thoracoabdominal DH. This is most likely occurred because in DH non-responders
556 PEEPe did not closely match PEEPi (14), confirming earlier concerns that the fixed
557 IPAP and EPAP were probably suboptimal, at least for DH non-responders (10, 48).
558 DH non-responders may have benefited if the expiratory pressure was automatically
559 tailored to the individual to overcome expiratory flow limitation, whilst avoiding
560 excessive pressures.

561 Furthermore, inspiratory EMG muscle activity was lower with pNIV compared to PLB
562 as the high inspiratory positive airway pressure (18 cmH₂O) was effective in
563 overcoming inspiratory flow limitation, thereby necessitating less effort from the
564 inspiratory muscles. Reduced work of breathing with inspiratory positive airway
565 pressure is possibly associated with lower dyspnoea (20). Interestingly, in DH non-
566 responders, dyspnoea was significantly lower in the pNIV trial compared to PLB. This
567 is attributed to the finding that inspiratory muscle (intercostal and scalene) activity
568 was significantly greater with PLB compared to the pNIV (Table 3), thereby inducing
569 a greater rise in perceived inspiratory difficulty (23, 37).

570 ***Thoracoabdominal volumes during exercise and in recovery***

571 In the present study, thoracoabdominal volume at total lung capacity increased from
572 baseline during exercise by an average of 326 ml. This finding is in agreement with a
573 previous study in which COPD patients progressively increased thoracoabdominal
574 volumes at total lung capacity by approximately 200 ml, during a ramp incremental
575 exercise protocol (49). However, despite the fact that patients in the present study
576 performed intermittent submaximal exercise, we report greater increase in
577 thoracoabdominal volumes at total lung capacity compared to that study (49). This
578 might be attributed to the application of pNIV during the recovery periods between
579 exercise bouts, which increased end-inspiratory thoracoabdominal volume in both
580 DH responders and DH non-responders. Importantly, in both DH responders and DH
581 non-responders end-expiratory thoracoabdominal volume did not recover towards
582 quiet breathing by five minutes into recovery. This is in keeping with the studies (41,
583 49) that found that dynamic hyperinflation 3-5 minutes into recovery from symptom
584 limited exercise was greater than at baseline. The present study extends these
585 findings by showing that in both DH responders and DH non-responders, rib cage
586 hyperinflation during exercise and recovery should have enhanced the threshold

587 loading of the muscles of the rib cage compartment so that recovery of
588 hyperinflation would take longer to return to baseline (41).

589 ***Haemodynamic responses***

590 Previous studies have reported that application of NIV in patients with COPD at rest
591 reduces cardiac output (4, 11). Our short application time of pNIV (1-min) in both DH
592 responders and DH non responders may have prevented adverse circulatory effects;
593 this is in contrast to the existing literature where NIV application exceeded 5 minutes
594 and resulted in adverse circulatory responses (4, 5, 11, 24).

595 ***Study limitations***

596 Some outcomes were clinically, but not statistically, significant. This may simply
597 reflect the limited sample size and a definitive outcome may have been achieved in a
598 larger population. The present study was powered to identify differences in the rate
599 of DH between pNIV and PLB. Moreover, we did not measure PEEPi and work of
600 breathing. Measurement of PEEPi could have helped us compare the differences
601 between PEEPe provided by pNIV and the actual PEEPi of DH responders and DH
602 non-responders; this in turn could have potentially further supported the
603 interpretation of our findings. Assessment of the work of breathing would have
604 allowed us compare our findings with the study by Petrof and colleagues (43) who
605 employed CPAP during exercise and further corroborate their findings as we
606 measured respiratory electromyography muscle activity. Although we only recorded
607 the EMG activation of the respiratory muscles during the recovery periods, it is
608 possible that signal could be contaminated by abdominal muscle activation for the
609 purposes of core stabilization whilst sitting on the cycle ergometer. The validity of
610 both surface EMG and NIRS recordings has been previously established (15, 29, 30).
611 Although we ensured that the quality of our measurements was sufficient to include
612 in our analysis, high adipose tissue on the abdomen is possible to have affected the
613 quality of the EMG and NIRS signals.

614 Furthermore, it is surprising that DH responders showed no difference in
615 breathlessness between pNIV and PLB application. This finding might be due to the
616 fixed duration of exercise as in our earlier study DH responders exercised for longer
617 compared to DH non-responders consequently to lower breathlessness at isotime
618 (10). Interestingly this earlier study from our group showed that in DH responders,
619 use of pNIV during daily activities over a 12-week period made them less anxious
620 about becoming breathlessness compared to DH non-responders (10).

621 Finally, in contrast to the existing literature using other NIV methods (39, 43)
622 inspiratory and expiratory positive airway pressures were fixed and could not be
623 adjusted for each patient in the present study. Accordingly, DH non-responders may

624 have responded well to different settings tailored to their physiological needs.
625 Individualized pressure titration using a NIV module with adjustable settings may
626 have provided more useful insight by clarifying whether an optimal pressure setting
627 exists that offers equivalent or superior relief compared to PLB. This technology
628 already exists, has been incorporated in standard home ventilators and could be
629 implemented in future pNIV devices. This warrants further studies to test this
630 possibility. We did not assess the reproducibility of physiological measures during
631 the pNIV and PLB trials to avoid exposure of patients to additional exercise testing.

632 ***Clinical implications***

633 The delayed recovery of dynamic hyperinflation following cessation of intermittent
634 exercise has important clinical implications when designing rehabilitative exercise
635 training regimes for patients with severe COPD, particularly if NIV is to be applied
636 only during recovery from exercise. It is apparent from our results that whilst acute
637 pNIV application was effective only in a specific subgroup of patients, clinical
638 characteristics such as baseline hyperinflation can help predict response.
639 Furthermore, COPD patients whose breathing control resembles that of a healthy
640 individual in recruiting expiratory muscles during exercise (1, 50) are more likely to
641 benefit from NIV; they may mitigate rib cage dynamic hyperinflation by expiratory
642 abdominal muscle recruitment. Nevertheless, DH non-responders were less
643 breathless and had greater expiratory flow with pNIV, therefore pNIV was not
644 without some benefit even to this subgroup of patients. During recovery from
645 exercise the improvement in DH lasted only transiently (1-min, during pNIV
646 application) in DH responders. If implementing the use of NIV in the pulmonary
647 rehabilitation setting NIV should perhaps be applied for longer to facilitate complete
648 recovery of DH before moving to a new exercise task. However, considering the
649 variation in response we have reported, it is important that clinicians assess the
650 response to pNIV on an individual basis in order to verify whether using a portable
651 NIV device during rehabilitation or at home makes the patient feeling better or
652 worse. An earlier study from our group showed that in DH responders, use of pNIV
653 during daily activities over a 12-week period made them less anxious about
654 becoming breathlessness compared to DH non-responders (10).

655

656 ***Conclusions***

657 COPD patients most likely to benefit from NIV in their recovery from exercise are
658 those who are able, during exercise and in recovery from exercise, to mitigate end-
659 expiratory rib cage dynamic hyperinflation by expiratory abdominal muscle
660 recruitment alongside increased expiratory flow rates.

661 **Acknowledgments**

662 We thank our patients for their considerable patience during this investigation.

663

664 **Grants**

665 The study was supported by Philips Respironics (HRC-GRA-17,030-VBREATHE-SH),
666 Northumbria Healthcare NHS Foundation Trust and Northumbria University
667 Newcastle.

668

669 **Disclosure**

670 The authors declare that they have no competing interests.

671 **References**

- 672 1. **Aliverti A.** *Mechanics of Breathing- New Insights from New Technologies.* 2014.
- 673 2. **Aliverti A, and Pedotti A.** Opto-electronic Plethysmography. In: *Mechanics of*
674 *Breathing*, edited by Aliverti A, Brusasco V, Macklem PT, and Pedotti A. Milano: Springer
675 Milan, 2002, p. 47-59.
- 676 3. **Ambrosino N, and Cigni P.** Non invasive ventilation as an additional tool for exercise
677 training. *Multidisciplinary respiratory medicine* 10: 14, 2015.
- 678 4. **Ambrosino N, Nava S, Torbicki A, Riccardi G, Fracchia C, Opasich C, and Rampulla C.**
679 Haemodynamic effects of pressure support and PEEP ventilation by nasal route in patients
680 with stable chronic obstructive pulmonary disease. *Thorax* 48: 523-528, 1993.
- 681 5. **Baratz DM, Westbrook PR, Shah PK, and Mohsenifar Z.** Effect of nasal continuous
682 positive airway pressure on cardiac output and oxygen delivery in patients with congestive
683 heart failure. *Chest* 102: 1397-1401, 1992.
- 684 6. **Borg GA.** Psychophysical bases of perceived exertion. *Med Sci Sports Exerc* 14: 377-
685 381, 1982.
- 686 7. **Borghi-Silva A, Mendes RG, Toledo AC, Malosá Sampaio LM, da Silva TP,**
687 **Kunikushita LN, Dutra de Souza HC, Salvini TF, and Costa D.** Adjuncts to physical training of
688 patients with severe COPD: oxygen or noninvasive ventilation? *Respiratory care* 55: 885-894,
689 2010.
- 690 8. **Cardoso DM, Fregonezi GA, Jost RT, Gass R, Alberton CL, Albuquerque IM, Paiva**
691 **DN, and Barreto SS.** Acute effects of Expiratory Positive Airway Pressure (EPAP) on different
692 levels in ventilation and electrical activity of sternocleidomastoid and parasternal muscles in
693 Chronic Obstructive Pulmonary Disease (COPD) patients: a randomized controlled trial.
694 *Brazilian journal of physical therapy* 20: 525-534, 2016.
- 695 9. **Charloux A, Lonsdorfer-Wolf E, Richard R, Lampert E, Oswald-Mammosser M,**
696 **Mettauer B, Geny B, and Lonsdorfer J.** A new impedance cardiograph device for the non-
697 invasive evaluation of cardiac output at rest and during exercise: comparison with the
698 "direct" Fick method. *Eur J Appl Physiol* 82: 313-320, 2000.
- 699 10. **Chynkiamis N, Armstrong M, Hume E, Alexiou C, Snow L, Lane ND, Hartley T,**
700 **Bourke SC, and Vogiatzis I.** Effect of portable non-invasive ventilation on exercise tolerance
701 in COPD: One size does not fit all. *Respiratory physiology & neurobiology* 277: 103436, 2020.
- 702 11. **Diaz O, Iglesia R, Ferrer M, Zavala E, Santos C, Wagner PD, Roca J, and Rodriguez-**
703 **Roisin R.** Effects of noninvasive ventilation on pulmonary gas exchange and hemodynamics
704 during acute hypercapnic exacerbations of chronic obstructive pulmonary disease. *American*
705 *journal of respiratory and critical care medicine* 156: 1840-1845, 1997.
- 706 12. **Diaz O, Villafranca C, Ghezzi H, Borzone G, Leiva A, Milic-Emil J, and Lisboa C.** Role
707 of inspiratory capacity on exercise tolerance in COPD patients with and without tidal
708 expiratory flow limitation at rest. *Eur Respir J* 16: 269-275, 2000.
- 709 13. **Eltayara L, Becklake MR, Volta CA, and Milic-Emili J.** Relationship between chronic
710 dyspnea and expiratory flow limitation in patients with chronic obstructive pulmonary
711 disease. *American journal of respiratory and critical care medicine* 154: 1726-1734, 1996.
- 712 14. **Gay PC, Rodarte JR, and Hubmayr RD.** The effects of positive expiratory pressure on
713 isovolume flow and dynamic hyperinflation in patients receiving mechanical ventilation. *The*
714 *American review of respiratory disease* 139: 621-626, 1989.
- 715 15. **Gilleard WL, and Brown JM.** An electromyographic validation of an abdominal
716 muscle test. *Archives of physical medicine and rehabilitation* 75: 1002-1007, 1994.
- 717 16. **Grubler MR, Wigger O, Berger D, and Blochlinger S.** Basic concepts of heart-lung
718 interactions during mechanical ventilation. *Swiss medical weekly* 147: w14491, 2017.
- 719 17. **Hardy W, and Jasko J.** Evaluation of a Portable Positive Pressure Device to Relieve
720 Dyspnea During Exercise in COPD Patients. 2015.

- 721 18. **Hyatt RE.** Expiratory flow limitation. *Journal of applied physiology: respiratory,*
722 *environmental and exercise physiology* 55: 1-7, 1983.
- 723 19. **Johnson JE, Gavin DJ, and Adams-Dramiga S.** Effects of training with heliox and
724 noninvasive positive pressure ventilation on exercise ability in patients with severe COPD.
725 *Chest* 122: 464-472, 2002.
- 726 20. **Kallet RH, and Diaz JV.** The physiologic effects of noninvasive ventilation. *Respir*
727 *Care* 54: 102-115, 2009.
- 728 21. **Koulouris NG, Dimopoulou I, Valta P, Finkelstein R, Cosio MG, and Milic-Emili J.**
729 Detection of expiratory flow limitation during exercise in COPD patients. *Journal of Applied*
730 *Physiology* 82: 723-731, 1997.
- 731 22. **Labeix P, Berger M, Court Fortune I, Feasson L, Verges S, and Costes F.** Quadriceps
732 Endurance Increases Following Cycling Exercise With Non-Invasive Ventilation In Moderate-
733 To-Severe COPD Patients. A Non-Randomized Controlled Study. *Int J Chron Obstruct Pulmon*
734 *Dis* 14: 2461-2468, 2019.
- 735 23. **Laveneziana P, Webb KA, Wadell K, Neder JA, and O'Donnell DE.** Does expiratory
736 muscle activity influence dynamic hyperinflation and exertional dyspnea in COPD? *Respir*
737 *Physiol Neurobiol* 199: 24-33, 2014.
- 738 24. **Leech JA, and Ascah KJ.** Hemodynamic effects of nasal CPAP examined by Doppler
739 echocardiography. *Chest* 99: 323-326, 1991.
- 740 25. **Louvaris Z, Habazettl H, Wagner H, Zakyntinos S, Wagner P, and Vogiatzis I.** Near-
741 infrared spectroscopy using indocyanine green dye for minimally invasive measurement of
742 respiratory and leg muscle blood flow in patients with COPD. *Journal of applied physiology*
743 *(Bethesda, Md : 1985)* 125: 947-959, 2018.
- 744 26. **Louvaris Z, Spetsioti S, Andrianopoulos V, Chynkiamis N, Habazettl H, Wagner H,**
745 **Zakyntinos S, Wagner PD, and Vogiatzis I.** Cardiac output measurement during exercise in
746 COPD: A comparison of dye dilution and impedance cardiography. *Clin Respir J* 13: 222-231,
747 2019.
- 748 27. **Macklem PT.** Exercise in COPD: damned if you do and damned if you don't. *Thorax*
749 60: 887-888, 2005.
- 750 28. **Mahmood SS, and Pinsky MR.** Heart-lung interactions during mechanical
751 ventilation: the basics. *Annals of translational medicine* 6: 349, 2018.
- 752 29. **Mancini DM, Bolinger L, Li H, Kendrick K, Chance B, and Wilson JR.** Validation of
753 near-infrared spectroscopy in humans. *J Appl Physiol (1985)* 77: 2740-2747, 1994.
- 754 30. **Marshall P, and Murphy B.** The validity and reliability of surface EMG to assess the
755 neuromuscular response of the abdominal muscles to rapid limb movement. *Journal of*
756 *electromyography and kinesiology : official journal of the International Society of*
757 *Electrophysiological Kinesiology* 13: 477-489, 2003.
- 758 31. **Milesi I, Porta R, Barbano L, Cacciatore S, Vitacca M, and Dellacà RL.** Automatic
759 tailoring of the lowest PEEP to abolish tidal expiratory flow limitation in seated and supine
760 COPD patients. *Respir Med* 155: 13-18, 2019.
- 761 32. **Milesi I, Porta R, Cacciatore S, Vitacca M, Dellacà R, and Barbano L.** Effects of
762 automatic tailoring of Positive End Expiratory Pressure (PEEP) by Forced Oscillation
763 Technique (FOT) during nocturnal Non-Invasive Ventilation (NIV) in Chronic Obstructive
764 Pulmonary Disease (COPD). *European Respiratory Journal* 50: PA2179, 2017.
- 765 33. **Milic-Emili J.** Inspiratory capacity and exercise tolerance in chronic obstructive
766 pulmonary disease. *Canadian respiratory journal* 7: 282-285, 2000.
- 767 34. **Nasis I, Kortianou E, Vasilopoulou M, Spetsioti S, Louvaris Z, Kaltsakas G, Davos CH,**
768 **Zakyntinos S, Koulouris NG, and Vogiatzis I.** Hemodynamic effects of high intensity interval
769 training in COPD patients exhibiting exercise-induced dynamic hyperinflation. *Respiratory*
770 *physiology & neurobiology* 217: 8-16, 2015.

- 771 35. **O'Donnell DE, Ciavaglia CE, and Neder JA.** When obesity and chronic obstructive
772 pulmonary disease collide. Physiological and clinical consequences. *Ann Am Thorac Soc* 11:
773 635-644, 2014.
- 774 36. **O'Donnell DE, D'Arsigny C, and Webb KA.** Effects of hyperoxia on ventilatory
775 limitation during exercise in advanced chronic obstructive pulmonary disease. *American*
776 *journal of respiratory and critical care medicine* 163: 892-898, 2001.
- 777 37. **O'Donnell DE, Hamilton AL, and Webb KA.** Sensory-mechanical relationships during
778 high-intensity, constant-work-rate exercise in COPD. *Journal of applied physiology*
779 *(Bethesda, Md : 1985)* 101: 1025-1035, 2006.
- 780 38. **O'Donnell DE, Reville SM, and Webb KA.** Dynamic hyperinflation and exercise
781 intolerance in chronic obstructive pulmonary disease. *American journal of respiratory and*
782 *critical care medicine* 164: 770-777, 2001.
- 783 39. **O'Donnell DE, Sani R, Giesbrecht G, and Younes M.** Effect of continuous positive
784 airway pressure on respiratory sensation in patients with chronic obstructive pulmonary
785 disease during submaximal exercise. *The American review of respiratory disease* 138: 1185-
786 1191, 1988.
- 787 40. **O'Donnell DE, and Webb KA.** Exertional breathlessness in patients with chronic
788 airflow limitation. The role of lung hyperinflation. *The American review of respiratory disease*
789 148: 1351-1357, 1993.
- 790 41. **O'Donnell D, Johnson B, Richter K, Kesten S, and Hamilton A.** Inspiratory capacity
791 and dyspnoea during recovery from symptom-limited exercise in COPD patients treated with
792 tiotropium. *Eur Respir J* 24: 214s, 2004.
- 793 42. **Paton J, Swaminathan S, Sargent C, and Keens T.** Expiratory muscle endurance and
794 the oxygen cost of expiration in normal adults. In: *CLINICAL RESEARCH* SLACK INC 6900
795 GROVE RD, THOROFARE, NJ 08086, 1989, p. A214-A214.
- 796 43. **Petrof BJ, Calderini E, and Gottfried SB.** Effect of CPAP on respiratory effort and
797 dyspnea during exercise in severe COPD. *Journal of applied physiology (Bethesda, Md : 1985)*
798 69: 179-188, 1990.
- 799 44. **Renston JP, DiMarco AF, and Supinski GS.** Respiratory muscle rest using nasal BiPAP
800 ventilation in patients with stable severe COPD. *Chest* 105: 1053-1060, 1994.
- 801 45. **Reuveny R, Ben-Dov I, Gaides M, and Reichert N.** Ventilatory support during
802 training improves training benefit in severe chronic airway obstruction. *Isr Med Assoc J* 7:
803 151-155, 2005.
- 804 46. **Tan KH, Lai FO, and Hwang NC.** Measurement of cardiac output using Physio Flow
805 with different positions of electrode placement. *Singapore Med J* 47: 967-970, 2006.
- 806 47. **Toledo A, Borghi-Silva A, Sampaio LM, Ribeiro KP, Baldissera V, and Costa D.** The
807 impact of noninvasive ventilation during the physical training in patients with moderate-to-
808 severe chronic obstructive pulmonary disease (COPD). *Clinics (Sao Paulo)* 62: 113-120, 2007.
- 809 48. **Vogiatzis I, Chynkiamis N, Armstrong M, Lane ND, Hartley T, Gray WK, and Bourke**
810 **SC.** Intermittent Use of Portable NIV Increases Exercise Tolerance in COPD: A Randomised,
811 Cross-Over Trial. *J Clin Med* 8: 94, 2019.
- 812 49. **Vogiatzis I, Georgiadou O, Golemati S, Aliverti A, Kosmas E, Kastanakis E, Geladas**
813 **N, Koutsoukou A, Nanas S, Zakyntinos S, and Roussos C.** Patterns of dynamic
814 hyperinflation during exercise and recovery in patients with severe chronic obstructive
815 pulmonary disease. *Thorax* 60: 723-729, 2005.
- 816 50. **Vogiatzis I, and Zakyntinos S.** Factors limiting exercise tolerance in chronic lung
817 diseases. *Compr Physiol* 2: 1779-1817, 2012.
- 818 51. **WorldMedicalAssociation.** Declaration of Helsinki World Medical Associaton.
819 <https://www.wma.net/what-we-do/medical-ethics/declaration-of-helsinki/>. [14 Jan, 2019].

820

Figures legends

821

822

823 **Figure 1.** Effect of the application of portable non-invasive ventilation (pNIV) (closed
824 symbols) compared to pursed lip breathing (PLB) (open symbols) on: a) total
825 thoracoabdominal volume, b) rib cage volume and c) abdominal volume in all patients.
826 Circles: end-expiratory volume, triangles: end-inspiratory volume, rhombuses: total
827 thoracoabdominal volume. Grey area highlights acute application of pNIV or PLB. Data are
828 presented as mean \pm SEM. QB: quiet breathing, REC: recovery. * $p < 0.05$ pNIV vs PLB.

829

830 **Figure 2.** Effect of the application of portable non-invasive ventilation (pNIV) (closed
831 symbols) compared to pursed lip breathing (PLB) (open symbols) in DH responders (left
832 panel) and DH non-responders (right panel) on: a & d) total thoracoabdominal volume, b &
833 e) rib cage volume and c & f) abdominal volume. Circles: end-expiratory volume, triangles:
834 end-inspiratory volume, rhombuses: total thoracoabdominal volume. Grey area highlights
835 acute application of pNIV or PLB. Data are presented as mean \pm SEM. QB: quiet breathing,
836 REC: recovery. * $p < 0.05$ pNIV vs PLB, † $p < 0.05$ QB vs exercise in end-expiratory volume, §;
837 minimum clinical importance difference between pNIV and PLB.

838


839 **Figure 3.** Effect of the application of portable non-invasive ventilation (pNIV) (closed
840 symbols) compared to pursed lip breathing (PLB) (open symbols) in DH responders (circles)
841 and DH non-responders (triangles) on: a) inspiratory flow rate and b) expiratory flow rate.
842 Data are presented as mean \pm SEM. QB: quiet breathing, REC: recovery.* $p < 0.05$ pNIV vs
843 PLB, † $p < 0.05$ between responders versus non-responders with pNIV.

844

845 **Figure 4.** Effect of the application of portable non-invasive ventilation (pNIV) (closed
846 symbols) compared to pursed lip breathing (PLB) (open symbols) in DH responders (left
847 panel) and DH non-responders (right panel) on: a & d) stroke volume, b & e) heart rate and c
848 & f) cardiac output. Data are presented as mean \pm SEM. QB: quiet breathing, REC: recovery.
849 * $p < 0.05$ pNIV vs PLB.

850

Figure 1








Figure 3







Table 1 Patient Demographic data

| | All patients (n=14) | DH Responders (n=7) | DH Non-responders (n=7) | p |
|---------------------------------------|------------------------|------------------------|----------------------------|-------|
| Age (years) | 68.4±8.4 | 67.7±6.1 | 69.1±10.7 | 0.764 |
| BMI (kg/m ²) | 28.6±7.2 | 32.8±6.7 | 24.4±5.0 | 0.022 |
| FEV ₁ (L) | 1.34±0.69 | 1.53±0.81 | 1.14±0.53 | 0.301 |
| FEV ₁ (% predicted) | 55±22 | 56±23 | 54±21 | 0.861 |
| FVC (L) | 2.91±1.07 | 3.28±1.00 | 2.53±1.08 | 0.204 |
| FVC (% predicted) | 95±26 | 93±22 | 96±31 | 0.876 |
| FEV ₁ /FVC | 45±13 | 45±14 | 45±12 | 0.984 |
| TLC (% predicted) | 126±36 | 134±41 | 117±30 | 0.432 |
| FRC (% predicted) | 151±56 | 167±62 | 135±50 | 0.355 |
| RV (% predicted) | 173±81 | 191±93 | 155±71 | 0.465 |
| IC (% predicted) | 63±18 | 68±20 | 58±16 | 0.319 |
| IC/TLC (%) | 35±10 | 34±8 | 37±13 | 0.581 |
| RV/TLC (%) | 53±14 | 53±14 | 53±15 | 0.984 |
| DLco (% predicted) | 50±19 | 50±24 | 49±15 | 0.930 |
| Inspiratory flow rate (L/sec) | 0.5±0.2 | 0.6±0.2 | 0.4±0.1 | 0.042 |
| Expiratory flow rate (L/sec) | 0.3±0.1 | 0.3±0.2 | 0.3±0.1 | 0.266 |
| WRpeak (Watts) | 56±27 | 63±31 | 49±21 | 0.097 |
| WRpeak (% predicted) | 54±30 | 52±39 | 56±22 | 0.778 |
| VO ₂ peak (% predicted) | 71±19 | 72±19 | 69±20 | 0.758 |
| ΔIC peak (ml) | -575±246 | -621±173 | -529±309 | 0.501 |

BMI, body mass index; FEV₁, forced expiratory volume in the first second; FVC, forced vital capacity; TLC, total lung capacity; FRC, functional residual capacity; RV, residual volume; IC, inspiratory capacity; DLco, transfer factor of the lung for carbon monoxide; WRpeak, peak work rate; VO₂peak, peak oxygen uptake; ΔIC, change from baseline in inspiratory capacity; values presented as mean ± SD for all baseline characteristics.

Table 2. Breathing pattern and symptoms during acute application of pNIV and PLB

| | Responders | | | Non-Responders | | |
|--------------------------------------|------------|-----------|-------|----------------|----------|-------|
| | pNIV | PLB | p | pNIV | PLB | p |
| V_T (L) | 1.9±0.7 | 1.4±0.5 | 0.002 | 1.1±0.3* | 1.2±0.4 | 0.369 |
| bf (breaths/min) | 21±3 | 22±5 | 0.478 | 27±5* | 20±4 | 0.002 |
| V_E (L/min) | 39.0±16.6 | 32.5±12.4 | 0.009 | 29.1±7.6 | 23.4±9.2 | 0.018 |
| Ti (sec) | 1.1±0.2 | 1.2±0.3 | 0.454 | 1.0±0.2 | 1.3±0.3 | 0.019 |
| Te (sec) | 1.9±0.4 | 1.8±0.3 | 0.765 | 1.3±0.3* | 2.1±0.6 | 0.001 |
| Ttot (sec) | 3.0±0.4 | 3.0±0.5 | 0.828 | 2.3±0.4* | 3.4±0.8 | 0.001 |
| Inspiratory flow rate (L/sec) | 1.8±0.6 | 1.4±0.5 | 0.001 | 1.2±0.4* | 1.0±0.4 | 0.064 |
| Expiratory flow rate (L/sec) | 1.1±0.5 | 0.9±0.4 | 0.048 | 0.9±0.2 | 0.7±0.3 | 0.011 |
| IRV (ml) | 200±446 | 502±477 | 0.078 | 240±549 | 444±246 | 0.252 |
| Dyspnoea (Borg) | 3.1±1.3 | 3.0±1.3 | 0.745 | 2.5±0.7 | 3.6±1.1 | 0.001 |
| Leg Discomfort (Borg) | 3.8±1.7 | 3.9±2.0 | 0.880 | 3.5±0.9 | 4.0±1.5 | 0.203 |

pNIV: portable non-invasive ventilation, PLB: pursed lip breathing, V_T: tidal volume, bf: breathing frequency, V_E: minute ventilation, Ti: inspiratory time; Te: expiratory time; Ttot: duty cycle time, IRV: inspiratory reserve volume *; p<0.05 responders versus non-responders with pNIV application. Data presented as mean ± SD

Table 3. Electromyographic activity of respiratory muscles during acute application of pNIV or PLB

| | Responders | | | Non-Responders | | |
|--|------------|--------|-------|----------------|--------|-------|
| | pNIV | PLB | p | pNIV | PLB | p |
| Intercostal (% baseline) | 111±26 | 91±28 | 0.043 | 103±33 | 135±70 | 0.009 |
| Scalene (% baseline) | 192±81 | 142±38 | 0.013 | 143±43 | 175±79 | 0.047 |
| Rectus abdominis (% baseline) | 175±126 | 108±25 | 0.014 | 179±140 | 146±59 | 0.049 |

pNIV; portable non-invasive ventilation, PLB pursed lip breathing. Data presented as mean ± SD of the fractional change in electromyographic activity from baseline values

Table 4. Respiratory muscle oxygen availability

| | Responders | | | Non-Responders | | |
|--|------------|----------|-------|----------------|----------|-------|
| | pNIV | PLB | p | pNIV | PLB | p |
| ΔHbO₂ intercostal (μmol/L) | -2.0±4.2 | -3.4±3.0 | 0.120 | -1.7±1.6 | -2.4±2.1 | 0.449 |
| ΔHbO₂ abdominal (μmol/L) | 0.8±1.0 | -0.2±1.5 | 0.421 | 0.8±6.2 | -3.3±3.9 | 0.378 |
| ΔHHb intercostal (μmol/L) | 3.5±3.0 | 1.2±1.4 | 0.048 | 5.3±3.7 | 3.2±4.7 | 0.040 |
| ΔHHb abdominal (μmol/L) | 4.6±1.7 | 2.8±3.8 | 0.047 | 3.5±3.3 | -1.1±1.8 | 0.045 |
| ΔTOI intercostal (%) | -3.0±1.9 | -4.0±2.2 | 0.597 | -3.4±1.1 | -2.6±1.9 | 0.505 |
| ΔTOI abdominal (%) | -4.1±3.2 | -3.0±2.7 | 0.070 | -5.8±2.6 | -1.6±2.7 | 0.031 |

pNIV; portable non-invasive ventilation, PLB; pursed lip breathing, ΔHbO₂: change in oxygenated haemoglobin from baseline, ΔHHb: change in deoxygenated haemoglobin from baseline, ΔTOI: change in tissue oxygen index from baseline. Data are presented as mean ± SD